Equilibrative nucleoside transporter 1

iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
星期日, 四月 7, 2024
Adenosine, Patient, Neoplasm, AACR, TILS, Therapy, Equilibrative nucleoside transporter 1, ENT1, Pharmaceutical industry

In preclinical studies, blockade of intracellular adenosine accumulation by EOS-984 enabled proliferation of memory T cells and TILs despite high adenosine concentrations, resulting in the restoration of T cell function and enhanced tumor cell killing.

Key Points: 
  • In preclinical studies, blockade of intracellular adenosine accumulation by EOS-984 enabled proliferation of memory T cells and TILs despite high adenosine concentrations, resulting in the restoration of T cell function and enhanced tumor cell killing.
  • Due to its mechanism of action, EOS-984 holds potential as a combination partner beyond anti-PD-1 therapy, including other immuno-oncology agents, cell therapies, and bispecific T cell engagers.
  • EOS-984 is currently in the dose escalation portion of a Phase 1 trial in advanced malignancies.
  • Topline data from the Phase 1 trial is anticipated in the second half of 2024.

iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
星期三, 三月 6, 2024
Investment, NSCLC, Therapy, The, Cancer, Metabolism, Merck, Research, Research and development, Equilibrative nucleoside transporter 1, SITC, AACR, Koch Institute, Hub, ENT1, Immunity, Comprehension, Adenosine, Lymphocyte, Merck & Co., Administration, Patient, TIGIT, Survival, Place of birth, HNSCC, Immune system, Pharmaceutical industry

WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Key Points: 
  • and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.
  • “With the recent developments in the TIGIT field, we believe belrestotug is in an advantageous position and are excited for its future prospects.
  • We look forward to sharing updates from our Phase 2 trials focused on 1L NSCLC and 1L HNSCC in 2024.
  • On December 7, 2023, iTeos announced the appointment of David K. Lee to the Company’s Board of Directors.

iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
星期二, 三月 5, 2024
Therapy, Equilibrative nucleoside transporter 1, ENT1, AACR, PM, Patient

WATERTOWN, Mass.

Key Points: 
  • WATERTOWN, Mass.
  • and GOSSELIES, Belgium, March 05, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced a poster presentation of preclinical data on EOS-984, a first-in-class small molecule antagonist targeting equilibrative nucleoside transporter 1 (ENT1), at the American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, California.
  • Date and Time: Sunday, April 7, 2024, 1:30 PM - 5:00 p.m. PT

iTeos Announces 2024 Strategic Priorities and Anticipated Milestones

Retrieved on: 
星期一, 一月 8, 2024
IO, ENT1, Survival, Place of birth, PD-1, Therapy, GSK, Lymphocyte, HNSCC, Patient, TIGIT, NSCLC, Equilibrative nucleoside transporter 1, Pharmaceutical industry

WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today outlined business updates and strategic priorities for 2024.

Key Points: 
  • and GOSSELIES, Belgium, Jan. 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today outlined business updates and strategic priorities for 2024.
  • “Over the past twelve months, the TIGIT competitive landscape has substantially evolved, further positioning iTeos and GSK as a potential leader with our high-quality TIGIT:PD-1 doublet, belrestotug + dostarlimab.
  • The Company plans to integrate IO-001 biomarker knowledge into the development strategy of future inupadenant clinical trials.
  • The Company continues to expect its cash balance to provide runway through 2026, which includes the initiation of multiple Phase 3 registrational trials assessing the belrestotug + dostarlimab doublet.